October 1 and 2, 2015
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of all deaths in the U.S., the most recent available data showing it was the primary cause of death for >76,000 women and >68,000 men 45 and over in 2013 (CDC Wonder accessed on September 24, 2015).
The National Heart, Lung, and Blood Institute (NHLBI) convened a working group meeting consisting of experts in multi-level intervention research on September 15 and 16, 2015. The purpose of the meeting was to provide recommendations that would be useful for designing and implementing multi-level interventions that target hard-to-reach, high risk or vulnerable populations and communities.
Sarcoidosis is an enigmatic disease characterized pathologically by granulomatous inflammation in the lung, heart, brain, eyes, skin, liver and other organs. It remains unclear why patients’ disease manifestations, severity and long-term prognoses vary so widely among the individuals affected.
On June 29-30, 2015, the NHLBI, with co-funding from the NIH Office of Disease Prevention, sponsored a workshop in Bethesda, Maryland, on Cardiovascular and Pulmonary Disease and the Emergence of e-cigarettes. The goal of the meeting was to identify specific gaps in existing research evidence that, if closed, would clarify the acute and chronic pulmonary and cardiovascular health effects of e-cigarette use.
Committed to its mission of conducting and supporting research that addresses the health needs of all sectors of the nation’s population, the Division of Lung Diseases, National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI/NIH) seeks to identify issues that impact the training and retention of underrepresented individuals in the biomedical research workforce, assess the effectiveness of its current approaches, and subsequently improve its strategies toward achieving this goal.
At a joint NHLBI and FDA workshop in May 2015, participants proposed research and policy priorities to address the risk of thrombosis in patients with ventricular assist devices.
To apply recent advances in sleep/circadian sciences to approaches leading to the development of biomarkers for studies of sleep/circadian function, point of care diagnosis of related sleep disorders, and assessing the risk of associated diseases of the heart, lung, blood, and aging.
On March 25-26, 2015, the NHLBI sponsored a meeting on the state of the science in transfusion medicine on the NIH campus in Bethesda. The goal of this meeting was to identify important research questions that could be answered in the next 5-10 years and that have the potential to transform the clinical practice of transfusion medicine.